Search Videos and More

Showing 25 - 35 of 35 results

Previous| 1 | 2 | 3 |Next


Triplet Therapy Shows Promise in Phase 2 Study in Chronic Lymphocytic Leukemia News

Triplet Therapy Shows Promise in Phase 2 Study in Chronic Lymphocytic Leukemia

Dana-Farber researchers find that combining a BCL-2 inhibitor with two other targeted agents is active in previously untreated CLL patients.
FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma Podcast

FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma

Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.
Hematologic Malignancies CME News

Hematologic Malignancies CME

The care of patients with hematologic malignancies is evolving rapidly. These video highlights will discuss new developments in the diagnosis and treatment of hematologic malignancies, as presented at the 2020 Annual Meeting of the American Society of Hematology (ASH).
Researchers Focus on How to Invigorate ‘Exhausted’ T-Cells in Immunotherapy News

Researchers Focus on How to Invigorate ‘Exhausted’ T-Cells in Immunotherapy

Despite the sometimes-dramatic success of new cancer immunotherapies like checkpoint inhibitor drugs and CAR T cells, thus far only a minority of patients have responded or gained long-lasting benefits.
In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow Transplant News

In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow Transplant

An immune-suppressing drug normally used to treat rheumatoid arthritis could make bone marrow transplant safer, report researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. In a Phase 2 multi-center trial, the drug abatacept (ORENCIA®) reduced rates of severe, acute graft-versus-host disease (GVHD) and boosted rates of survival without acute GVHD or relapse in patients with leukemia and other blood cancers.
First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients News

First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients

The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers and physicians at Dana-Farber Cancer Institute.
Next Questions: Chronic Lymphocytic Leukemia Video

Next Questions: Chronic Lymphocytic Leukemia

Jennifer Brown, MD, PhD, shares about multiple treatments and drug therapies and how long patients can remain on them while determining the best outcomes.
Dana-Farber to Offer First CAR T-Cell Therapy for Indolent Follicular Lymphoma Following FDA Approval News

Dana-Farber to Offer First CAR T-Cell Therapy for Indolent Follicular Lymphoma Following FDA Approval

The Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for indolent follicular lymphoma, a slow growing, non-Hodgkin lymphoma (NHL), represents a key advance for patients with relapsed or refractory forms of the disease. Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will be a certified treatment center for the therapy.
Break Through Cancer Launches Collaborative Model Across Top U.S. Research Institutions in Pursuit of Cancer Cures News

Break Through Cancer Launches Collaborative Model Across Top U.S. Research Institutions in Pursuit of Cancer Cures

Break Through Cancer today announced its formal launch as a public foundation designed to find new solutions to the most intractable challenges in cancer.
CAR T-Cell Therapy Generates Lasting Remissions in Patients with Multiple Myeloma News

CAR T-Cell Therapy Generates Lasting Remissions in Patients with Multiple Myeloma

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
Targeted Therapy for Children with Leukemia Can Provide Substantial Benefit, Study Finds News

Targeted Therapy for Children with Leukemia Can Provide Substantial Benefit, Study Finds

Testing tumor tissue for genetic alterations that can be targeted by drugs, a mainstay of treatment in a variety of cancers, can benefit many children with leukemia, investigators at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center report in a new study. In some cases, such therapy can be lifesaving.

Showing 25 - 35 of 35 results

Previous| 1 | 2 | 3 |Next